{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-024849","form_type":"8-K","ticker":"CTNM","cik":"0001855175","company_name":"Contineum Therapeutics, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.386992+00:00","generated_at":"2026-05-17T20:59:43.496958+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Contineum Q2 net loss $16M, cash $175.5M; PIPE-307 VISTA top line data Q4 2025","bullets":["Net loss of $16.0M for Q2 2025 vs $9.0M in Q2 2024; R&D expenses $14.1M (+78% YoY).","Cash and marketable securities $175.5M as of June 30, 2025; cash runway through 2027.","PIPE-307 Phase 2 VISTA (RRMS) top line data expected Q4 2025; PIPE-791 PET data Q3 2025.","Global PIPE-791 Phase 2 IPF trial initiation planned Q4 2025; PrMS and CTX-343 postponed.","Johnson & Johnson Phase 2 Moonlight-1 trial of PIPE-307 in MDD recruiting 124 participants."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-024849","json":"https://secwatch.observer/filing/0001437749-25-024849.json","markdown":"https://secwatch.observer/filing/0001437749-25-024849.md","text":"https://secwatch.observer/filing/0001437749-25-024849.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925024849/0001437749-25-024849-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925024849/ctnm20250616_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:59:43.496958+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}